The civic record
Read. Follow. Verify.Congressional Hearing: FDA Oversight of the Infant Formula Shortage
Record date · January 1, 2023
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
This document is a transcript of a House Subcommittee hearing held on May 11, 2023, to investigate the FDA's response to the infant formula shortage. Lawmakers questioned FDA officials regarding delays in facility inspections, the handling of reports, and the transparency of the agency's internal reviews.
The hearing examines the federal government's regulatory failures and response timeline regarding the 2022 infant formula crisis, which resulted in nationwide supply shortages for families.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
Parents and Caregivers
They experienced limited access to infant formula due to the supply shortage.
Food and Drug Administration
The agency is subject to congressional oversight regarding its regulatory and inspection protocols.
Abbott
The company's manufacturing facility in Sturgis, Michigan, was the subject of FDA inspections and recall actions.
Key Facts
- The hearing took place on May 11, 2023, as part of the 118th Congress.
- The Subcommittee investigated why it took four months for FDA inspectors to arrive at the Abbott facility in Sturgis, Michigan, after reports of infant illnesses.
- The FDA inspected only 3 of 23 infant formula manufacturing facilities in 2023.
- Lawmakers questioned the independence of the 'Solomon Report' regarding the FDA's crisis response.
Show all 7 facts
- The hearing addressed allegations that the FDA failed to investigate whistleblower warnings.
- An 'Infant Formula Timeline' document was submitted by Rep. Grothman.
- An FDA inspection report from March 2022 was submitted by Rep. Porter.
Frequently Asked Questions
What was the purpose of this hearing?
What specific facility was discussed?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceFull breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
FDA Inspection Frequency
The hearing highlights a significant gap in FDA oversight, noting that only 3 of 23 infant formula facilities were inspected in 2023.
Connected Entities
Sources
www.govinfo.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy75Intensity of disagreement among stakeholders
- Entertainment40Compellingness for a non-policy-wonk reader
- Buzz30Current news / social attention level
Publisher tools